Navigation Links
Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:5/6/2009

2009 2008 ASSETS Current Assets: Cash and cash equivalents $57,005 $76,315 Short-term investments (including restricted investments) 1,067 2,282 Accounts receivable, net 727 822 Inventories, net 1,507 1,892 Recoverable income taxes 5,526 5,526 Prepaid expenses and other current assets 2,275 2,782 Total current assets 68,107 89,619 Deferred income taxes, net 4,500 4,200 Property and equipment, net 1,273 1,393 Other assets (including restricted cash and investments) 3,103 3,010 Total assets $76,983 $98,222 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $5,636 $5,888 Deferred revenues 371 451 Other current liabilities 16,652 18,650 Total current liabilities 22,659 24,989 Other liabilities 10,230 9,809 Commitments and contingencies Stockholders' Equity: Preferred stock - $.01 par value 4,000,000 shares authorized; no shares issued - - Common stock - $.01 par value 150,000,000 shares authorized; 54,960,000 issued and outstanding at March 31, 2009 and 54,654,000 shares issued and outstanding at December 31, 2008
'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
2. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
3. Savient Submits Biologics License Application (BLA) for pegloticase
4. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
5. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
6. Savient Announces Appointment of David Gionco as Chief Financial Officer
7. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
8. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... PARK, N.C. , Aug. 27, 2015 /PRNewswire/ ... the decision by FedEx, UPS and The US ... certain biological specimens classified as ,select agents, by ... long history of handling these sensitive shipments. ... of global transportation regulations, trained and certified personnel ...
(Date:8/26/2015)... 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended June 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... to our Oral Amp B program, rapidly advancing ... Andrew Rae , President & CEO of ...
(Date:8/26/2015)... MIAMI , Aug. 26, 2015  The ... at the University of Miami Miller School of ... its clinical trial to test for the first ... was successfully completed.  This FDA approved Phase I/II ... islet transplantation and is an important first step ...
(Date:8/26/2015)... 26, 2015 Israel Proves Its Place in ... st place  Wayerz comes in 5 th ... by venture capital fund JVP, with Chinese consulting firm ... China , Israel , ... Impressive achievement for the Israeli representatives in the final round ...
Breaking Biology Technology:Marken Ensures Safe Transportation Of Select Agents And Toxins 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6
... havoc on bacteria as well as humans and, just like ... Professor John van der Oost, at the Society for General ... system" could be used to keep industrial microbes at peak ... Wageningen University in the Netherlands have spent the last three ...
... ... minutes post-dose using electronic patient diary data , ... PITTSBURGH, PA (Vocus) March 31, 2010 -- invivodata, ... global clinical research, today announced that its DiaryPRO® field-based ePRO solution captured ...
... system senses and tracks down infection in the body by ... cells manipulate their movement in response to external signals could ... but also how cancer cells spread through the body and ... Society for General Microbiology,s spring meeting in Edinburgh, Dr Holger ...
Cached Biology Technology:invivodata Delivers Critical Symptom Relief Data in INSYS Therapeutics' Breakthrough Cancer Pain Trial 2invivodata Delivers Critical Symptom Relief Data in INSYS Therapeutics' Breakthrough Cancer Pain Trial 3How immune cells 'sniff out' bacteria 2
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 /PRNewswire/ ... announced today it will unveil its "Guardian S" snake ... the National Tactical Officers Association Conference on August 30 ... S is the first-ever commercially available energetically autonomous snake ... and in-field trials and is protected by more than ...
(Date:8/20/2015)... ., Aug. 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... it has joined The Smart Card Alliance and the ... Card Alliance and the Smart Card Alliance Latin America ... to industry peers and thought leaders promoting adoption of ...
(Date:8/12/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is proud to announce that ... eClinical technology platform, has led the way to significant ... of 2015.   Q2 2015 and Q1 2015 were, ... contract value sold in the company,s 15 year history.  ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
... which become accustomed to ignoring genetically engineered chemical alarms ... become easy prey for ladybugs. That,s good news for ... for Plant Research and Cornell University. ( Proceedings of ... The study, "Alarm pheromone habituation in Myzus persicae ...
... Research is continually emerging on the impacts ... ecosystems and communities. Ecological scientists will discuss widespread ... plants in the wild to the implications of ... exploring society,s reactive mode toward environmental disasters in ...
... cell division, microtubules emanating from each of the spindle ... Scientists at the European Molecular Biology Laboratory (EMBL) in ... the extent of this overlap. In a study published ... reconstruct such anti-parallel microtubule overlaps in vitro, and identify ...
Cached Biology News:Apathetic aphids with attitude become easier prey for ladybugs 2Scientists find new evidence of genetically modified plants in the wild 2Scientists find new evidence of genetically modified plants in the wild 3Scientists find new evidence of genetically modified plants in the wild 4Constant overlap 2